Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Meistrich, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meistrich, M. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 8, No. 1, pp. 8-10, 1993
© 1993 European Society of Human Reproduction and Embryology

other

Potential genetic risks of using semen collected during chemotherapy

Marvin L. Meistrich

Department of Experimental Radiotherapy, Box 66, The University of Texas M. D. Anderson Cancer Center 1515 Holcombe Boulevard, Houston, TX 77030, USA

The results of many studies on the effects of mutagens on germ cells of the testes indicate that the recommendation of Carson et al. (Hum. Reprod., 6, 992–994, 1989) that semen samples collected during chemotherapy and cryopreserved may be safely used for insemination is incorrect because of the large potential for genetic risk to the offspring. Data from experimental animals, which indicate high levels of mutagenic effects in offspring from matings during or soon after treatment of the male with chemotherapy or radiation, are reviewed. The relevance of these data to the human situation is discussed. Based on these results, I recommend that patients not only complete their semen cryopreservation prior to the initiation of chemotherapy, but that they practice reliable contraception from the time of initiation of treatment until 6 months after completion of treatment.

Key words: birth defects/chemotherapy/cryopreservation/mutations/sperm


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer
Medical Treatment of Advanced Testicular Cancer
JAMA, February 13, 2008; 299(6): 672 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
G. A. Haines, J. H. Hendry, C. P. Daniel, and I. D. Morris
Germ Cell and Dose-Dependent DNA Damage Measured by the Comet Assay in Murine Spermatozoaa after Testicular X-Irradiation
Biol Reprod, September 1, 2002; 67(3): 854 - 861.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
P. De Mas, M. Daudin, M.-C. Vincent, G. Bourrouillou, P. Calvas, R. Mieusset, and L. Bujan
Increased aneuploidy in spermatozoa from testicular tumour patients after chemotherapy with cisplatin, etoposide and bleomycin
Hum. Reprod., June 1, 2001; 16(6): 1204 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
G. Horne, A. Atkinson, D.R. Brison, J. Radford, J.A.L. Yin, E.C.O. Edi-Osagie, E.H.E. Pease, and B.A. Lieberman
Achieving pregnancy against the odds: successful implantation of frozen-thawed embryos generated by ICSI using spermatozoa banked prior to chemo/radiotherapy for Hodgkin's disease and acute leukaemia: Case Report
Hum. Reprod., January 1, 2001; 16(1): 107 - 109.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.